An avian cell line designed for production of highly attenuated viruses

Vaccine

Volumn 27, Issue 5, 2009, Pages 748-756

  Jordan, Ingo ^a   Vos, Ad ^b   Beilfuß, Stefanie ^b   Neubert, Andreas ^b   Breul, Sabine ^c   Sandig, Volker ^a  

^a PROBIOGEN AG   (Germany)

^b IDT Biologika GmbH   (Germany)

^c Orvia ^*  (France)

Author keywords

AGE1.CR.pIX; Avian cell line; Heat shock; MVA

Indexed keywords

HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; AVIAN CELL LINE; CELL LINE; CONTROLLED STUDY; DUCK; HEAT SHOCK; HUMAN; HUMAN ADENOVIRUS; HUMAN CELL; NONHUMAN; PIX GENE; PRIORITY JOURNAL; STABLE EXPRESSION; STRUCTURAL GENE; VACCINE PRODUCTION; VIRUS ATTENUATION;

ADENOVIRIDAE; ANIMALS; CAPSID PROTEINS; CELL LINE; DUCKS; HUMANS; PLAQUE ASSAY; VACCINIA VIRUS; VIRUS CULTIVATION;

EID: 58249123674     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.066     Document Type: Article

References (39)

1. Meyer H., Sutter G., and Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72 Pt 5 (1991) 1031-1038
2. Sutter G., and Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 89 22 (1992) 10847-10851
3. Sutter G., Wyatt L.S., Foley P.L., Bennink J.R., and Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12 11 (1994) 1032-1040
4. Drillien R., Spehner D., and Hanau D. Modified vaccinia virus Ankara induces moderate activation of human dendritic cells. J Gen Virol 85 Pt 8 (2004) 2167-2175
5. Liu L., Chavan R., and Feinberg M.B. Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. BMC Immunol 9 (2008) 15
6. Mayr A. Smallpox vaccination and bioterrorism with pox viruses. Comp Immunol Microbiol Infect Dis 26 5-6 (2003) 423-430
7. Cebere I., Dorrell L., McShane H., Simmons A., McCormack S., Schmidt C., et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24 4 (2006) 417-425
8. Dorrell L., Williams P., Suttill A., Brown D., Roberts J., Conlon C., et al. Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA, HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. Vaccine 25 17 (2007) 3277-3283
9. Reed L.J., and Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 27 (1938) 493-497
10. Emeny J.M., and Morgan M.J. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J Gen Virol 43 1 (1979) 247-252
11. Weissmahr R.N., Schupbach J., and Boni J. Reverse transcriptase activity in chicken embryo fibroblast culture supernatants is associated with particles containing endogenous avian retrovirus EAV-0 RNA. J Virol 71 4 (1997) 3005-3012
12. Boni J., Stalder J., Reigel F., and Schupbach J. Detection of reverse transcriptase activity in live attenuated virus vaccines. Clin Diagn Virol 5 1 (1996) 43-53
13. Shoyab M., and Baluda M.A. Homology between avian oncornavirus RNAs and DNA from several avian species. J Virol 16 6 (1975) 1492-1502
14. Sears R.C., and Nevins J.R. Signaling networks that link cell proliferation and cell fate. J Biol Chem 277 14 (2002) 11617-11620
15. Yew P.R., Liu X., and Berk A.J. Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53. Genes Dev 8 2 (1994) 190-202
16. Martin M.E., and Berk A.J. Adenovirus E1B 55K represses p53 activation in vitro. J Virol 72 4 (1998) 3146-3154
17. Frisch S.M., and Mymryk J.S. Adenovirus-5 E1A: paradox and paradigm. Nat Rev Mol Cell Biol 3 6 (2002) 441-452
18. Sargent K.L., Meulenbroek R.A., and Parks R.J. Activation of adenoviral gene expression by protein IX is not required for efficient virus replication. J Virol 78 10 (2004) 5032-5037
19. Colby W.W., and Shenk T. Adenovirus type 5 virions can be assembled in vivo in the absence of detectable polypeptide IX. J Virol 39 3 (1981) 977-980
20. Rosa-Calatrava M., Puvion-Dutilleul F., Lutz P., Dreyer D., de The H., Chatton B., et al. Adenovirus protein IX sequesters host-cell promyelocytic leukaemia protein and contributes to efficient viral proliferation. EMBO Rep 4 10 (2003) 969-975
21. Ullman A.J., Reich N.C., and Hearing P. Adenovirus E4 ORF3 protein inhibits the interferon-mediated antiviral response. J Virol 81 9 (2007) 4744-4752
22. Boyer J., Rohleder K., and Ketner G. Adenovirus E4 34k and E4 11k inhibit double strand break repair and are physically associated with the cellular DNA-dependent protein kinase. Virology 263 2 (1999) 307-312
23. Baccala R., Hoebe K., Kono D.H., Beutler B., and Theofilopoulos A.N. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 13 5 (2007) 543-551
24. Weber F., Wagner V., Rasmussen S.B., Hartmann R., and Paludan S.R. Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J Virol 80 10 (2006) 5059-5064
25. Alexopoulou L., Holt A.C., Medzhitov R., and Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 6857 (2001) 732-738
26. Lutz P., Rosa-Calatrava M., and Kedinger C. The product of the adenovirus intermediate gene IX is a transcriptional activator. J Virol 71 7 (1997) 5102-5109
27. la Cour T., Kiemer L., Molgaard A., Gupta R., Skriver K., and Brunak S. Analysis and prediction of leucine-rich nuclear export signals. Protein Eng Des Sel 17 6 (2004) 527-536
28. Santoro M.G., Rossi A., and Amici C. NF-kappaB and virus infection: who controls whom. EMBO J 22 11 (2003) 2552-2560
29. Gaudernak E., Seipelt J., Triendl A., Grassauer A., and Kuechler E. Antiviral effects of pyrrolidine dithiocarbamate on human rhinoviruses. J Virol 76 12 (2002) 6004-6015
30. Melville M.W., Tan S.L., Wambach M., Song J., Morimoto R.I., and Katze M.G. The cellular inhibitor of the PKR protein kinase, P58 (IPK), is an influenza virus-activated co-chaperone that modulates heat shock protein 70 activity. J Biol Chem 274 6 (1999) 3797-3803
31. Glotzer J.B., Saltik M., Chiocca S., Michou A.I., Moseley P., and Cotten M. Activation of heat-shock response by an adenovirus is essential for virus replication. Nature 407 6801 (2000) 207-211
32. Hung J.J., Chung C.S., and Chang W. Molecular chaperone Hsp90 is important for vaccinia virus growth in cells. J Virol 76 3 (2002) 1379-1390
33. Kamal A., Thao L., Sensintaffar J., Zhang L., Boehm M.F., Fritz L.C., et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425 6956 (2003) 407-410
34. Kosano H., Stensgard B., Charlesworth M.C., McMahon N., and Toft D. The assembly of progesterone receptor-hsp90 complexes using purified proteins. J Biol Chem 273 49 (1998) 32973-32979
35. Connor J.H., McKenzie M.O., Parks G.D., and Lyles D.S. Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses. Virology 362 1 (2007) 109-119
36. Queitsch C., Sangster T.A., and Lindquist S. Hsp90 as a capacitor of phenotypic variation. Nature 417 6889 (2002) 618-624
37. Krougliak V., and Graham F.L. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Hum Gene Ther 6 12 (1995) 1575-1586
38. Imler J.L., Chartier C., Dreyer D., Dieterle A., Sainte-Marie M., Faure T., et al. Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors. Gene Ther 3 1 (1996) 75-84
39. Caravokyri C., and Leppard K.N. Constitutive episomal expression of polypeptide IX (pIX) in a 293-based cell line complements the deficiency of pIX mutant adenovirus type 5. J Virol 69 11 (1995) 6627-6633